BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 21193695)

  • 1. Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction.
    Zhong F; Harr MW; Bultynck G; Monaco G; Parys JB; De Smedt H; Rong YP; Molitoris JK; Lam M; Ryder C; Matsuyama S; Distelhorst CW
    Blood; 2011 Mar; 117(10):2924-34. PubMed ID: 21193695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor.
    Rong YP; Bultynck G; Aromolaran AS; Zhong F; Parys JB; De Smedt H; Mignery GA; Roderick HL; Bootman MD; Distelhorst CW
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14397-402. PubMed ID: 19706527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
    Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
    Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
    Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
    Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
    Akl H; Monaco G; La Rovere R; Welkenhuyzen K; Kiviluoto S; Vervliet T; Molgó J; Distelhorst CW; Missiaen L; Mikoshiba K; Parys JB; De Smedt H; Bultynck G
    Cell Death Dis; 2013 May; 4(5):e632. PubMed ID: 23681227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive IP
    Bittremieux M; La Rovere RM; Akl H; Martines C; Welkenhuyzen K; Dubron K; Baes M; Janssens A; Vandenberghe P; Laurenti L; Rietdorf K; Morciano G; Pinton P; Mikoshiba K; Bootman MD; Efremov DG; De Smedt H; Parys JB; Bultynck G
    Cell Death Differ; 2019 Mar; 26(3):531-547. PubMed ID: 29899382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Bcl-2-IP
    Distelhorst CW
    Biochim Biophys Acta Mol Cell Res; 2018 Nov; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
    Akl H; La Rovere RM; Janssens A; Vandenberghe P; Parys JB; Bultynck G
    Int J Dev Biol; 2015; 59(7-9):391-8. PubMed ID: 26260683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor.
    Rong YP; Barr P; Yee VC; Distelhorst CW
    Biochim Biophys Acta; 2009 Jun; 1793(6):971-8. PubMed ID: 19056433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2 interaction with the inositol 1,4,5-trisphosphate receptor: role in Ca(2+) signaling and disease.
    Distelhorst CW; Bootman MD
    Cell Calcium; 2011 Sep; 50(3):234-41. PubMed ID: 21628070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl.
    Monaco G; Decrock E; Akl H; Ponsaerts R; Vervliet T; Luyten T; De Maeyer M; Missiaen L; Distelhorst CW; De Smedt H; Parys JB; Leybaert L; Bultynck G
    Cell Death Differ; 2012 Feb; 19(2):295-309. PubMed ID: 21818117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
    Monaco G; La Rovere R; Karamanou S; Welkenhuyzen K; Ivanova H; Vandermarliere E; Di Martile M; Del Bufalo D; De Smedt H; Parys JB; Economou A; Bultynck G
    FEBS J; 2018 Jan; 285(1):127-145. PubMed ID: 29131545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feedback regulation mediated by Bcl-2 and DARPP-32 regulates inositol 1,4,5-trisphosphate receptor phosphorylation and promotes cell survival.
    Chang MJ; Zhong F; Lavik AR; Parys JB; Berridge MJ; Distelhorst CW
    Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1186-91. PubMed ID: 24395794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca
    Kerkhofs M; La Rovere R; Welkenhuysen K; Janssens A; Vandenberghe P; Madesh M; Parys JB; Bultynck G
    Cell Calcium; 2021 Mar; 94():102333. PubMed ID: 33450506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals.
    Rong YP; Aromolaran AS; Bultynck G; Zhong F; Li X; McColl K; Matsuyama S; Herlitze S; Roderick HL; Bootman MD; Mignery GA; Parys JB; De Smedt H; Distelhorst CW
    Mol Cell; 2008 Jul; 31(2):255-65. PubMed ID: 18657507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP
    Ivanova H; Luyten T; Decrock E; Vervliet T; Leybaert L; Parys JB; Bultynck G
    Cell Calcium; 2017 Mar; 62():41-46. PubMed ID: 28179071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcl-2-Protein Family as Modulators of IP
    Ivanova H; Vervliet T; Monaco G; Terry LE; Rosa N; Baker MR; Parys JB; Serysheva II; Yule DI; Bultynck G
    Cold Spring Harb Perspect Biol; 2020 Apr; 12(4):. PubMed ID: 31501195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.
    Vervloessem T; Sasi BK; Xerxa E; Karamanou S; Kale J; La Rovere RM; Chakraborty S; Sneyers F; Vogler M; Economou A; Laurenti L; Andrews DW; Efremov DG; Bultynck G
    Cell Death Dis; 2020 Sep; 11(9):769. PubMed ID: 32943617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bcl-2 and Bax protein interaction in B-lymphocytes of peripheral blood in patients with chronic lymphocytic leukemia].
    Brajusković G; Orolicki SV; Cerović S; Usaj SK; Marjanović S; Romac S
    Vojnosanit Pregl; 2005 May; 62(5):357-63. PubMed ID: 15913039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gold Cluster Capped with a BCL-2 Antagonistic Peptide Exerts Synergistic Antitumor Activity in Chronic Lymphocytic Leukemia Cells.
    Yao Y; Lu C; Gao L; Cao K; Yuan H; Zhang X; Gao X; Yuan Q
    ACS Appl Mater Interfaces; 2021 May; 13(18):21108-21118. PubMed ID: 33942607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.